Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Philippe Gautret, Jean‐Christophe Lagier, Philippe Parola, et al.
Travel Medicine and Infectious Disease (2020) Vol. 34, pp. 101663-101663
Open Access | Times Cited: 763

Showing 1-25 of 763 citing articles:

Immunology of COVID-19: Current State of the Science
Nicolas Vabret, Graham J. Britton, Conor Gruber, et al.
Immunity (2020) Vol. 52, Iss. 6, pp. 910-941
Open Access | Times Cited: 1654
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby, Marion Mafham, Louise Linsell, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 21, pp. 2030-2040
Open Access | Times Cited: 1175
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 7, pp. 859-866
Open Access | Times Cited: 1128
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2020) Vol. 78, Iss. 7, pp. e83-e102
Open Access | Times Cited: 1010
Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19)
Arno R. Bourgonje, Amaal Eman Abdulle, Wim Timens, et al.
The Journal of Pathology (2020) Vol. 251, Iss. 3, pp. 228-248
Open Access | Times Cited: 985
COVID-19: Immunology and treatment options
Susanna Felsenstein, Jenny A. Herbert, Paul McNamara, et al.
Clinical Immunology (2020) Vol. 215, pp. 108448-108448
Open Access | Times Cited: 657
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Samia Arshad, Paul E. Kilgore, Zohra Chaudhry, et al.
International Journal of Infectious Diseases (2020) Vol. 97, pp. 396-403
Open Access | Times Cited: 556
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Matthieu Million, Jean‐Christophe Lagier, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 35, pp. 101738-101738
Open Access | Times Cited: 479
Antiviral treatment of COVID-19
Serap Şimşek Yavuz, Serhat Ünal
TURKISH JOURNAL OF MEDICAL SCIENCES (2020) Vol. 50, Iss. SI-1, pp. 611-619
Open Access | Times Cited: 359
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras, et al.
Nature (2020) Vol. 585, Iss. 7826, pp. 584-587
Open Access | Times Cited: 334
Emerging treatment strategies for COVID-19 infection
Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Eleni Korompoki, et al.
Clinical and Experimental Medicine (2020) Vol. 21, Iss. 2, pp. 167-179
Open Access | Times Cited: 316
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Julien Andréani, Marion Le Bideau, Isabelle Duflot, et al.
Microbial Pathogenesis (2020) Vol. 145, pp. 104228-104228
Open Access | Times Cited: 303
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial
Natàlia Casamitjana, Marc Corbacho-Monné, María Ubals, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e4073-e4081
Open Access | Times Cited: 278
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher Butler, Jienchi Dorward, Ly‐Mee Yu, et al.
The Lancet (2021) Vol. 397, Iss. 10279, pp. 1063-1074
Open Access | Times Cited: 272
SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review
Kavita Narang, Elizabeth Ann L. Enninga, Madugodaralalage Gunaratne, et al.
Mayo Clinic Proceedings (2020) Vol. 95, Iss. 8, pp. 1750-1765
Open Access | Times Cited: 264
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Jean‐Christophe Lagier, Matthieu Million, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 36, pp. 101791-101791
Open Access | Times Cited: 254
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Peter Horby, Marion Mafham, Louise Linsell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 239
Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China
You Shang, Chun Pan, Xianghong Yang, et al.
Annals of Intensive Care (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 235
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 233
Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey
Jean Franco Quispe-Cañari, Evelyn Fidel-Rosales, Diego Manrique, et al.
Saudi Pharmaceutical Journal (2020) Vol. 29, Iss. 1, pp. 1-11
Open Access | Times Cited: 231
When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19
Daniel Asfaw Erku, Sewunet Admasu Belachew, Solomon Abrha, et al.
Research in Social and Administrative Pharmacy (2020) Vol. 17, Iss. 1, pp. 1954-1963
Open Access | Times Cited: 225
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Xuping Xie, Antonio E. Muruato, Xianwen Zhang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 287-296
Closed Access | Times Cited: 220
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Katelyn A Pastick, Elizabeth C Okafor, Fan Wang, et al.
Open Forum Infectious Diseases (2020) Vol. 7, Iss. 4
Open Access | Times Cited: 208
Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: A systematic review and meta‐analysis
Phulen Sarma, Hardeep Kaur, Harish Kumar, et al.
Journal of Medical Virology (2020) Vol. 92, Iss. 7, pp. 776-785
Open Access | Times Cited: 200
Page 1 - Next Page

Scroll to top